NCT04815187

Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 39 (actual)
• Sponsor: House Ear Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate a previously FDA-approved medication that is known to help with allergy symptoms to see if it can decrease symptoms in patients with Meniere's Disease.

Conditions

• Meniere Disease
• Allergic Rhinitis
• Vertigo

Interventions

Type	Name	Description
DRUG	Montelukast	Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.
DRUG	Placebo	Each subject will be given a drug diary to record when they took the drug and any symptoms that they are experiencing, and will bring this diary and any unused pills to their next clinic visit before receiving the next 30-day supply. This process will continue for the full 90 days of study involvement, with a final visit 3 months later.

Timeline

• Start date: 2021-06-07
• Primary completion: 2025-09-03
• Completion: 2025-12-31
• First posted: 2021-03-24
• Last updated: 2025-03-18

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study